JPWO2007026829A1 - 小粒子低比重リポ蛋白の定量方法および定量キット - Google Patents
小粒子低比重リポ蛋白の定量方法および定量キット Download PDFInfo
- Publication number
- JPWO2007026829A1 JPWO2007026829A1 JP2007533333A JP2007533333A JPWO2007026829A1 JP WO2007026829 A1 JPWO2007026829 A1 JP WO2007026829A1 JP 2007533333 A JP2007533333 A JP 2007533333A JP 2007533333 A JP2007533333 A JP 2007533333A JP WO2007026829 A1 JPWO2007026829 A1 JP WO2007026829A1
- Authority
- JP
- Japan
- Prior art keywords
- cholesterol
- small
- dense ldl
- ldl
- polyoxyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004895 Lipoproteins Human genes 0.000 title claims abstract description 43
- 108090001030 Lipoproteins Proteins 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 41
- 230000005484 gravity Effects 0.000 title description 16
- 239000002245 particle Substances 0.000 title description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 162
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 81
- 238000008214 LDL Cholesterol Methods 0.000 claims abstract description 65
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims abstract description 50
- 102000004190 Enzymes Human genes 0.000 claims abstract description 33
- 108090000790 Enzymes Proteins 0.000 claims abstract description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims description 63
- 102000000019 Sterol Esterase Human genes 0.000 claims description 19
- 108010055297 Sterol Esterase Proteins 0.000 claims description 19
- 108010089254 Cholesterol oxidase Proteins 0.000 claims description 18
- 239000003945 anionic surfactant Substances 0.000 claims description 17
- 239000002736 nonionic surfactant Substances 0.000 claims description 16
- 108010023417 cholesterol dehydrogenase Proteins 0.000 claims description 14
- 108010085346 steroid delta-isomerase Proteins 0.000 claims description 14
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 13
- 102000043296 Lipoprotein lipases Human genes 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 13
- 238000011002 quantification Methods 0.000 claims description 8
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 7
- 108010064785 Phospholipases Proteins 0.000 claims description 7
- 102000015439 Phospholipases Human genes 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 127
- 102000007330 LDL Lipoproteins Human genes 0.000 description 127
- 239000000203 mixture Substances 0.000 description 37
- -1 polyoxyethylene Polymers 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 19
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 18
- 239000004094 surface-active agent Substances 0.000 description 17
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 16
- 108010028554 LDL Cholesterol Proteins 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 6
- 230000004931 aggregating effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229920001451 polypropylene glycol Polymers 0.000 description 6
- 239000000852 hydrogen donor Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000047703 Nonion Species 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 229920002114 octoxynol-9 Polymers 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- WNRGWPVJGDABME-UHFFFAOYSA-N 3,5-Dimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1 WNRGWPVJGDABME-UHFFFAOYSA-N 0.000 description 1
- DYPGTLUYQZIULN-UHFFFAOYSA-N 3-(3-methoxy-5-methylanilino)propane-1-sulfonic acid Chemical compound COC1=CC(C)=CC(NCCCS(O)(=O)=O)=C1 DYPGTLUYQZIULN-UHFFFAOYSA-N 0.000 description 1
- CDGBQMHYFARRCC-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC(C)=CC(C)=C1 CDGBQMHYFARRCC-UHFFFAOYSA-N 0.000 description 1
- IBSUMVZKDLDAEK-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(C)=C1 IBSUMVZKDLDAEK-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- NYLUYMWPXIIXDX-UHFFFAOYSA-N 3-(phenylazaniumyl)propane-1-sulfonate Chemical compound OS(=O)(=O)CCCNC1=CC=CC=C1 NYLUYMWPXIIXDX-UHFFFAOYSA-N 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 241001191009 Gymnomyza Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
- 101000847066 Homo sapiens Translin-associated protein X Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 229920002025 Pluronic® F 88 Polymers 0.000 description 1
- 229920002057 Pluronic® P 103 Polymers 0.000 description 1
- 102100032834 Translin-associated protein X Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical group OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SVLRFMQGKVFRTB-UHFFFAOYSA-M sodium;3-(3,5-dimethoxyanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].COC1=CC(NCC(O)CS([O-])(=O)=O)=CC(OC)=C1 SVLRFMQGKVFRTB-UHFFFAOYSA-M 0.000 description 1
- HLXGRHNZZSMNRX-UHFFFAOYSA-M sodium;3-(n-ethyl-3,5-dimethylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC(C)=CC(C)=C1 HLXGRHNZZSMNRX-UHFFFAOYSA-M 0.000 description 1
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 description 1
- ZPCAZHPYLUKSMY-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZPCAZHPYLUKSMY-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
RO-(C2H4O)a-(C3H6O)b-(C2H4O)c-H(I)
RO-(C3H6O)d-(C2H4O)e-(C3H6O)f-H(II)
[式中a、b、およびcならびにd、e、およびfは整数を表し、Rは水素原子または直鎖、分岐のアルキルを表す]
[式中x、yは整数を表す]
で表される化合物が挙げられる。(I)においてポリオキシプロピレンの数(式中のb)は1〜200が好ましく、20〜150がより好ましく、30〜100が特に好ましい。ポリオキシエチレンの数(式中のaおよびc)はそれぞれ1〜200が好ましく、1〜100がより好ましく、1〜60が特に好ましい。Rで示される直鎖または分岐のアルキル基としては炭素数1〜30が好ましく、炭素数2〜25が特に好ましい。(II)においてポリオキシプロピレンの数(式中のe)は20〜100が好ましく、ポリオキシエチレンの数(式中のdおよびf)はそれぞれ1〜60が好ましい。(III)においてポリオキシプロピレンの数(式中のy)は2〜30が好ましい。ポリオキシエチレンの数(式中のx)は1〜50が好ましく、1〜30が特に好ましい。
第2試薬組成物中に各種ポリオキシエチレン−ポリオキシプロピレン共重合体を用いた以下の試薬組成物を調製した。
実施例1の第2試薬組成物中に、更に非イオン性界面活性剤を添加した以下の試薬組成物を調製した。
被検体試料としてのヒト血清30例に対し、実施例2で使用した試薬組成物を用いて測定を行った。
実施例1の第2試薬組成物中に、更に陰イオン性界面活性剤を添加した以下の試薬組成物を調製した。
被検体試料としてのヒト血清30例に対し、実施例4で使用した試薬組成物を用いて測定を行った。
実施例1の第2試薬組成物中に、更にリポプロテインリパーゼを各0、2、4、5U/mL添加した以下の試薬組成物を調製した。
Claims (13)
- 被検体試料にポリオキシエチレン−ポリオキシプロピレン共重合体またはその誘導体の存在下にコレステロール測定用酵素を添加し、ポリオキシエチレン−ポリオキシプロピレン共重合体またはその誘導体をリポ蛋白質のうちsmall,dense LDLに選択的に作用させ、生成したコレステロール量を測定することを特徴とするsmall,dense LDLコレステロールの定量方法。
- さらに非イオン性および/または陰イオン性界面活性剤を添加することを特徴とする請求項1記載の方法。
- コレステロール測定用酵素がコレステロールエステラーゼならびにコレステロールオキシダーゼもしくはコレステロールデヒドロゲナーゼからなることを特徴とする請求項1または2に記載の方法。
- さらにホスホリパーゼおよび/またはリポプロテインリパーゼを添加することを特徴とする請求項1〜3のいずれか1項に記載の方法。
- ポリオキシエチレン−ポリオキシプロピレン共重合体またはその誘導体をリポ蛋白質のうちsmall,dense LDLに選択的に作用させる前に、small,dense LDL以外のリポ蛋白中のコレステロールをsmall,dense LDLコレステロール定量反応系外に導くことを特徴とする請求項1〜4のいずれか1項に記載の方法。
- 被検体試料にポリオキシエチレン−ポリオキシプロピレン共重合体またはその誘導体の存在下でコレステロール測定用酵素を添加し、ポリオキシエチレン−ポリオキシプロピレン共重合体またはその誘導体をリポ蛋白質のうちsmall,dense LDLに選択的に作用させ、生成したコレステロール量を測定するための、ポリオキシエチレン−ポリオキシプロピレン共重合体もしくはその誘導体ならびにコレステロール測定用酵素を含むsmall,dense LDLコレステロールの定量用キット。
- さらに非イオン性および/または陰イオン性界面活性剤を含む請求項6記載のsmall,dense LDLコレステロール定量用キット。
- コレステロール測定用酵素がコレステロールエステラーゼおよびコレステロールオキシダーゼまたはコレステロールデヒドロゲナーゼからなる請求項6または7に記載のsmall,dense LDLコレステロール定量用キット。
- さらにホスホリパーゼおよび/またはリポプロテインリパーゼを含む請求項6〜8のいずれか1項に記載のsmall,dense LDLコレステロール定量用キット。
- ポリオキシエチレン−ポリオキシプロピレン共重合体またはその誘導体をリポ蛋白質のうちsmall,dense LDLに選択的に作用させる前に、small,dense LDL以外のリポ蛋白中のコレステロールをsmall,dense LDLコレステロール定量反応系外に導くための試薬を含む請求項6〜9のいずれか1項に記載のsmall,dense LDLコレステロール定量用キット。
- 被検体試料中のsmall,dense LDLコレステロールを定量する方法において、被検体試料にポリオキシエチレン−ポリオキシプロピレン共重合体またはその誘導体の存在下にコレステロール測定用酵素を添加し、ポリオキシエチレン−ポリオキシプロピレン共重合体またはその誘導体をリポ蛋白質のうちsmall,dense LDLに選択的に作用させ、生成したコレステロールを測定する工程からなる方法。
- small,dense LDLコレステロールを含む被検体試料中のsmall,dense LDLコレステロールを定量するための、ポリオキシエチレン−ポリオキシプロピレン共重合体もしくはその誘導体を含むsmall,dense LDLコレステロール測定用試薬。
- small,dense LDLコレステロールを含む被検体試料中のsmall,dense LDLコレステロールを定量するための、ポリオキシエチレン−ポリオキシプロピレン共重合体のsmall,dense LDLコレステロール測定用試薬としての使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007533333A JP5042023B2 (ja) | 2005-08-31 | 2006-08-31 | 小粒子低比重リポ蛋白の定量方法および定量キット |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005252091 | 2005-08-31 | ||
JP2005252091 | 2005-08-31 | ||
JP2007533333A JP5042023B2 (ja) | 2005-08-31 | 2006-08-31 | 小粒子低比重リポ蛋白の定量方法および定量キット |
PCT/JP2006/317243 WO2007026829A1 (ja) | 2005-08-31 | 2006-08-31 | 小粒子低比重リポ蛋白の定量方法および定量キット |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012131602A Division JP5548733B2 (ja) | 2005-08-31 | 2012-06-11 | 小粒子低比重リポ蛋白の定量方法および定量キット |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007026829A1 true JPWO2007026829A1 (ja) | 2009-03-12 |
JP5042023B2 JP5042023B2 (ja) | 2012-10-03 |
Family
ID=37808912
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007533333A Active JP5042023B2 (ja) | 2005-08-31 | 2006-08-31 | 小粒子低比重リポ蛋白の定量方法および定量キット |
JP2012131602A Active JP5548733B2 (ja) | 2005-08-31 | 2012-06-11 | 小粒子低比重リポ蛋白の定量方法および定量キット |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012131602A Active JP5548733B2 (ja) | 2005-08-31 | 2012-06-11 | 小粒子低比重リポ蛋白の定量方法および定量キット |
Country Status (5)
Country | Link |
---|---|
US (1) | US8697378B2 (ja) |
EP (1) | EP1930442B1 (ja) |
JP (2) | JP5042023B2 (ja) |
DE (1) | DE602006018035D1 (ja) |
WO (1) | WO2007026829A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5081814B2 (ja) * | 2006-05-01 | 2012-11-28 | デンカ生研株式会社 | 家族性複合型高脂血症の検出方法 |
JP5111389B2 (ja) | 2006-10-18 | 2013-01-09 | 協和メデックス株式会社 | 小粒子低密度リポ蛋白中のコレステロールの定量方法 |
CA2679309C (en) * | 2007-02-28 | 2015-05-26 | Denka Seiken Co., Ltd. | Reagent for quantitative determination of small, dense ldls |
KR101586505B1 (ko) * | 2007-10-10 | 2016-01-18 | 덴카 세이켄 가부시키가이샤 | 소입자 고비중 ldl 콜레스테롤의 정량 방법 및 키트 |
JP5500777B2 (ja) * | 2008-03-06 | 2014-05-21 | デンカ生研株式会社 | Hdl3−cの測定方法及びhdl3−c測定用試薬 |
US20140147869A1 (en) * | 2010-10-29 | 2014-05-29 | Arkray, Inc. | Method and Kit for Measuring Cholesterol in Low-Density Lipoproteins |
JP6054051B2 (ja) * | 2012-04-11 | 2016-12-27 | デンカ生研株式会社 | 高密度リポ蛋白(hdl)中のコレステロール(−c)の亜分画定量方法 |
JP6729995B2 (ja) * | 2014-10-09 | 2020-07-29 | デンカ株式会社 | 免疫分析方法及び試薬 |
JP6851576B2 (ja) * | 2016-04-20 | 2021-03-31 | 日立化成ダイアグノスティックス・システムズ株式会社 | 検体中の脂質による濁り抑制剤 |
US20200392558A1 (en) * | 2017-09-01 | 2020-12-17 | Hitachi Chemical Diagnostics Systems Co., Ltd. | Method for measuring cholesterol in low-density lipoprotein, measurement reagent, and measurement kit |
CN111398607B (zh) * | 2019-01-03 | 2024-02-23 | 中元汇吉生物技术股份有限公司 | 一种小而密低密度脂蛋白胆固醇测定试剂 |
JP6869300B2 (ja) * | 2019-09-10 | 2021-05-12 | デンカ株式会社 | small,dense LDLコレステロールの定量方法およびキット |
JP6703175B1 (ja) * | 2019-09-10 | 2020-06-03 | デンカ生研株式会社 | キットおよび方法 |
CN110794155B (zh) * | 2019-11-26 | 2020-06-23 | 浙江夸烨生物科技有限公司 | 一种用于检测小而密低密度脂蛋白胆固醇的试剂盒及其检测方法 |
CN111551512B (zh) * | 2020-06-11 | 2023-07-25 | 安徽大千生物工程有限公司 | 一种高灵敏度和特异度的sdLDL-C比色法检测试剂盒及其制备使用方法 |
JP7437263B2 (ja) | 2020-07-31 | 2024-02-22 | デンカ株式会社 | 試薬組成物およびキット |
EP4428243A1 (en) * | 2021-11-02 | 2024-09-11 | Denka Company Limited | Reagent composition and kit |
WO2023199890A1 (ja) * | 2022-04-11 | 2023-10-19 | デンカ株式会社 | 試薬組成物およびキット |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5870208A (ja) | 1981-10-22 | 1983-04-26 | Toyo Contact Lens Co Ltd | コンタクトレンズ用洗浄剤 |
DE3220012A1 (de) * | 1982-05-27 | 1983-12-01 | Akzo Gmbh, 5600 Wuppertal | Polyaetherderivate und deren verwendung als dispergatoren in mitteln zum weichspuelen von textilien auf der basis quaternaerer ammoniumsalze |
US5858279A (en) * | 1997-10-31 | 1999-01-12 | Church & Dwight Co., Inc | Stabilized triple defoamer composition |
US6794157B1 (en) | 1998-09-18 | 2004-09-21 | Kyowa Medex Co., Ltd. | Methods for fractional quatification of cholesterol in lipoproteins and quantification reagents |
US6096702A (en) * | 1998-10-01 | 2000-08-01 | Imaginative Research Associates, Inc. | Post foaming clear gels and solutions |
JP2000325097A (ja) * | 1999-05-21 | 2000-11-28 | Showa Denko Kk | リポ蛋白質コレステロールの測定方法及び測定試薬 |
JP4456715B2 (ja) | 2000-02-28 | 2010-04-28 | 協和メデックス株式会社 | レムナント様リポ蛋白中のコレステロールの測定方法および測定試薬 |
KR101046898B1 (ko) * | 2002-10-16 | 2011-07-06 | 교와 메덱스 가부시키가이샤 | 고밀도 리포 단백질 중의 콜레스테롤의 측정 방법 및 시약 |
EP1571452B1 (en) * | 2002-12-06 | 2011-04-13 | DENKA SEIKEN Co., Ltd. | Method of quantifying small-sized low density lipoprotein |
-
2006
- 2006-08-31 US US12/065,125 patent/US8697378B2/en active Active
- 2006-08-31 DE DE602006018035T patent/DE602006018035D1/de active Active
- 2006-08-31 WO PCT/JP2006/317243 patent/WO2007026829A1/ja active Application Filing
- 2006-08-31 EP EP06797203A patent/EP1930442B1/en active Active
- 2006-08-31 JP JP2007533333A patent/JP5042023B2/ja active Active
-
2012
- 2012-06-11 JP JP2012131602A patent/JP5548733B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP5548733B2 (ja) | 2014-07-16 |
EP1930442A1 (en) | 2008-06-11 |
JP5042023B2 (ja) | 2012-10-03 |
JP2012165761A (ja) | 2012-09-06 |
EP1930442B1 (en) | 2010-11-03 |
WO2007026829A1 (ja) | 2007-03-08 |
US20090263844A1 (en) | 2009-10-22 |
DE602006018035D1 (de) | 2010-12-16 |
US8697378B2 (en) | 2014-04-15 |
EP1930442A4 (en) | 2008-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5042023B2 (ja) | 小粒子低比重リポ蛋白の定量方法および定量キット | |
JP5325093B2 (ja) | 小粒子低比重リポ蛋白の定量試薬 | |
JP5450080B2 (ja) | small,denseLDLコレステロールの定量方法およびキット | |
JP5111389B2 (ja) | 小粒子低密度リポ蛋白中のコレステロールの定量方法 | |
AU2005227961B2 (en) | Method of multiquantification for cholesterol of low-density lipoprotein | |
EP1849876B1 (en) | Method, reagent and kit for determination of cholesterol in remnant-like particles (rlp) | |
US20200131560A1 (en) | Blood sample assay method | |
JP2022107036A (ja) | リポ蛋白コレステロールの定量方法、定量試薬及び定量キット | |
EP2639310B1 (en) | Method for quantification of remnant-like lipoprotein cholesterol and kit for same | |
JP6829009B2 (ja) | トリグリセリドリッチリポ蛋白中のコレステロールの定量方法及び定量試薬 | |
JPWO2004055204A1 (ja) | 低密度リポ蛋白中コレステロールのマルチ定量法 | |
JP2011505866A (ja) | 脂質測定方法 | |
JP7396965B2 (ja) | small,dense LDLコレステロールの定量方法およびキット | |
JP7427522B2 (ja) | キットおよび方法 | |
WO2019177093A1 (ja) | 高密度リポ蛋白質中のコレステロールの定量方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090807 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120611 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120703 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120710 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5042023 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150720 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |